Exelixis Historical Balance Sheet
EXEL Stock | USD 36.38 0.77 2.16% |
Trend analysis of Exelixis balance sheet accounts such as Common Stock Shares Outstanding of 178.5 M or Liabilities And Stockholders Equity of 3.1 B provides information on Exelixis' total assets, liabilities, and equity, which is the actual value of Exelixis to its prevalent stockholders. By breaking down trends over time using Exelixis balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Exelixis latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Exelixis is a good buy for the upcoming year.
Exelixis Inventory |
|
Exelixis |
About Exelixis Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Exelixis at a specified time, usually calculated after every quarter, six months, or one year. Exelixis Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Exelixis and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Exelixis currently owns. An asset can also be divided into two categories, current and non-current.
Exelixis Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Exelixis assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Exelixis books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from Exelixis' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Exelixis current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.At this time, Exelixis' Property Plant And Equipment Net is quite stable compared to the past year. Accounts Payable is expected to rise to about 35.5 M this year, although the value of Common Stock Shares Outstanding will most likely fall to about 178.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 51.3M | 190.2M | 189.9M | 179.6M | Other Stockholder Equity | 2.4B | 2.5B | 2.4B | 1.4B |
Exelixis balance sheet Correlations
Click cells to compare fundamentals
Exelixis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Exelixis balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.9B | 2.1B | 2.6B | 3.1B | 2.9B | 3.1B | |
Total Stockholder Equity | 1.7B | 1.9B | 2.2B | 2.5B | 2.3B | 2.4B | |
Retained Earnings | (559.4M) | (447.6M) | (216.5M) | (34.2M) | (173.4M) | (182.0M) | |
Common Stock Shares Outstanding | 315.0M | 318.0M | 322.4M | 324.6M | 321.5M | 178.5M | |
Liabilities And Stockholders Equity | 1.9B | 2.1B | 2.6B | 3.1B | 2.9B | 3.1B | |
Other Stockholder Equity | 2.2B | 2.3B | 2.4B | 2.5B | 2.4B | 1.4B | |
Short Long Term Debt Total | 50.7M | 49.1M | 51.3M | 190.2M | 189.9M | 179.6M | |
Other Current Liab | 21.7M | 179.2M | 313.3M | 284.2M | 360.5M | 378.5M | |
Total Current Liabilities | 142.7M | 204.7M | 337.6M | 324.4M | 394.3M | 414.0M | |
Property Plant And Equipment Net | 90.7M | 67.4M | 104.0M | 401.2M | 470.9M | 494.4M | |
Net Debt | (215.8M) | (270.1M) | (595.9M) | (311.0M) | (73.1M) | (69.4M) | |
Accounts Payable | 11.6M | 23.6M | 24.3M | 32.7M | 33.8M | 35.5M | |
Cash | 266.5M | 319.2M | 647.2M | 501.2M | 263.0M | 190.9M | |
Non Current Assets Total | 874.5M | 691.9M | 781.5M | 1.5B | 1.6B | 1.7B | |
Non Currrent Assets Other | 11.3M | 71.9M | 131.0M | 290.6M | 334.2M | 350.9M | |
Cash And Short Term Investments | 852.2M | 1.2B | 1.5B | 1.3B | 995.3M | 1.0B | |
Net Receivables | 119.1M | 160.9M | 282.7M | 214.8M | 237.4M | 249.3M | |
Short Term Investments | 585.7M | 887.3M | 819.9M | 807.3M | 732.3M | 768.9M | |
Non Current Liabilities Total | 57.0M | 53.6M | 68.0M | 258.7M | 284.2M | 213.1M | |
Other Current Assets | 27.0M | 57.0M | 57.5M | 62.2M | 67.9M | 71.3M | |
Total Liab | 199.7M | 258.2M | 405.6M | 583.1M | 678.4M | 370.3M | |
Total Current Assets | 1.0B | 1.4B | 1.8B | 1.6B | 1.3B | 1.4B | |
Accumulated Other Comprehensive Income | 3.1M | 4.5M | (758K) | (14.5M) | (3.8M) | (3.9M) | |
Short Term Debt | 2.7M | 3.0M | 8.7M | 17.7M | 25.7M | 50.4M | |
Common Stock | 305K | 312K | 319K | 324K | 303K | 287.9K | |
Other Liab | 8.9M | 4.5M | 16.8M | 68.5M | 78.8M | 83.4M | |
Other Assets | 185.3M | 187.1M | 197.5M | 286.9M | 329.9M | 346.4M | |
Common Stock Total Equity | 300K | 305K | 312K | 324K | 372.6K | 391.2K | |
Inventory | 12.9M | 21.0M | 27.5M | 33.3M | 17.3M | 9.5M | |
Property Plant And Equipment Gross | 90.7M | 67.4M | 144.9M | 462.1M | 551.2M | 578.8M | |
Property Plant Equipment | 48.9M | 67.4M | 149.2M | 110.6M | 127.2M | 133.6M | |
Current Deferred Revenue | 106.7M | 1.8M | 8.7M | 6.6M | 5.4M | 5.1M | |
Net Tangible Assets | 1.6B | 1.8B | 2.0B | 2.4B | 2.8B | 2.9B | |
Retained Earnings Total Equity | (880.4M) | (559.4M) | (447.6M) | (34.2M) | (39.4M) | (41.3M) | |
Capital Surpluse | 2.2B | 2.2B | 2.3B | 2.5B | 2.9B | 2.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.